Nasus Pharma Enrolls And Doses First Patient In Phase 1 Study Of NS003 Intranasal Formulation Of Ondansetron
Share
Why It Matters
Nasus Pharma started testing a new nose spray medicine for nausea. Watch how well the medicine works and if patients like it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.